Additional file 1: of Lower respiratory tract microbial composition was diversified in Pseudomonas aeruginosa ventilator-associated pneumonia patients

Figure S1. Rarefaction curve of samples collected from P. aeruginosa VAP patients and control subjects. Control, control group; PA VAP, Pseudomonas aeruginosa VAP group. Figure S2. The LRT microbiota was different between P. aeruginosa VAP patients and control subjects. The unweighted unifrac distance between the LRT microbiota of each sample was calculated and it was shown as a Pcoa two-dimensional map. Each dot represents one sample. Control, control group; PAVAP, Pseudomonas aeruginosa VAP group. Figure S3. The LRT microbiota and hierarchical clustering of P. aeruginosa VAP patients at genus level. Initial samples were analyzed. The Bray curtis distance matrix (in genus level) was used to construct a dendrogram including 36 P. aeruginosa VAP patients. Clusters were separated by black dotted line originating from the top of the dendrogram. The microbial composition at genus level was visualized as bar charts. Patient number is indicated at the left of each bar. Each bar represents 100% of the OTUs detected per patient; OTUs are color-coded according to genus. LRT lower respiratory tract; VAP, ventilator-associated pneumonia; OTUs, operational taxonomic units. Figure S4. The Shannon diversity between different time points was stable in LRT samples from P. aeruginosa VAP patients. Comparison of the Shannon diversity between day1 (initial samples) and day7 (A), day1 and day14 (B) were conducted by paired non-parametric test (both Pâ >â 0.05). Figure S5. The variety of the relative abundance of Pseudomonas, Lactobacillus and Bifidobacterium in acute phase and improvement phase of P. aeruginosa VAP patients. Pseudomonas (A) showed a decreased trend while Lactobacillus (B) and Bifidobacterium (C) showed an increased trend when the P. aeruginosa VAP patients obtained clinical improvement. Figure S6. The LRT microbiota of survivors of P. aeruginosa VAP patients had no significant difference compared to that of the non-survivors. Samples from day1 were collected for analysis. The unweighted unifrac distance between the survivors and non-survivors was calculated and it was shown as a Pcoa two-dimensional map. Each dot represents one sample. Table S1. Baseline characteristics of control subjects and P. aeruginosa VAP patients. Table S2. Conventional culture of endotracheal aspiration samples from P. aeruginosa VAP patients. Table S3. Antibiotic use before one week sampling of P. aeruginosa VAP patients. Table S4. Antibiotics statistics of P. aeruginosa VAP patients before sampling. Table S5. Antibiotic use during the dynamic observation period of P. aeruginosa VAP patients. Table S6. Negative correlation between genus of P. aeruginosa VAP and SOFA score. (ZIP 1314 kb)